https://orcid.org/0000-0002-8841-9820
References
- BlayJ-Y. A decade of tyrosine kinase inhibitor therapy: historical and current perspectives on targeted therapy for GIST. Cancer Treat. Rev.37(5), 373–384 (2011).
- GounderMM , MakiRG. Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother. Pharmacol.67(1), 25–43 (2011).
- DemetriGD , van OosteromAT , GarrettCRet al.Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet368(9544), 1329–1338 (2006).
- DemetriGD , ReichardtP , KangY-Ket al.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, Phase III trial. Lancet Lond. Engl.381(9863), 295–302 (2013).
- FDA. Commissioner O of the FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors. (2020). https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-treat-rare-mutation-patients-gastrointestinal-stromal-tumors
- HeinrichMC , JonesRL , von MehrenMet al.Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol.21(7), 935–946 (2020).
- von MehrenM , SerranoC , BauerSet al.LBA87 - INVICTUS: a Phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753). Ann. Oncol.30, v925–v926 (2019).
- YooC , RyuM-H , JoJ , ParkI , RyooB-Y , KangY-K. Efficacy of imatinib in patients with platelet-derived growth factor receptor alpha–mutated gastrointestinal stromal tumors. Cancer Res. Treat. Off. J. Korean Cancer Assoc.48(2), 546–552 (2016).
- SinghAS , ChmielowskiB , HechtJRet al.A randomized Phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor (GIST). J. Clin. Oncol.37(Suppl. 15), 11017–11017 (2019).
- BauerS , GeorgeS , KangY-Ket al.VOYAGER: an open-label, randomised, Phase III study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST). Ann. Oncol.29, viii595 (2018).
- Avapritinib falls short in third- and fourth-line gastrointestinal stromal tumors. Target. Oncol.https://www.targetedonc.com/view/avapritinib-falls-short-in-third-and-fourth-line-gastrointestinal-stromal-tumors
- FDA. Research C for DE and FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation. (2020). https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation
- KimMS , LeeDH , LeeYRet al.A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate. Korean J. Hematol.45(1), 73–75 (2010).
- FekiJ , MarrekchiG , BoudawaraTet al.Subdural hematoma during therapy of gastro-intestinal stromal tumor (GIST) with Imatinib mesylate. Gulf J. Oncolog.1(17), 92–95 (2015).
- GebreyohannesYK , WozniakA , ZhaiM-Eet al.Robust activity of avapritinib, potent and highly selective inhibitor of mutated kit, in patient-derived xenograft models of gastrointestinal stromal tumors. Clin. Cancer Res.25(2), 609–618 (2019).
- HeinrichMC , GriffithD , McKinleyAet al.Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.18(16), 4375–4384 (2012).
- Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02847429
- WagnerAJ , KindlerH , GelderblomHet al.A Phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Ann. Oncol.28(3), 541–546 (2017).
- FlavahanWA , DrierY , JohnstoneSEet al.Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature575(7781), 229–233 (2019).
- BurgoyneA. An open-label, Phase II efficacy study of temozolomide (TMZ) in advanced succinate dehydrogenase (sdh)-mutant/deficient gastrointestinal stromal tumor (GIST). https://clinicaltrials.gov/ct2/show/NCT03556384